Ionis Pharmaceuticals, Inc. Investigation - IONS

Company
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)

Learn more about the Ionis Pharmaceuticals, Inc. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Ionis Pharmaceuticals, Inc. Investigation Details

Ionis Pharmaceuticals, Inc. shareholders lost money on November 9, 2026, when the stock fell sharply after the Company reported Q3 2026 financial results and reduced its full-year sales guidance for its key drug TRYNGOLZA by approximately 50%. For Q3 2026, the Company reported revenue of approximately $243 million, a net loss of $110 million, and nine-month losses of approximately $317 million. Although revenue and earnings per share beat consensus estimates, the Company lowered full-year TRYNGOLZA guidance from $100-110 million down to roughly $50 million. Management indicated "initial sales progress has been more gradual than anticipated." Elaborating during the earnings call, Chief Global Product Strategy Officer Kyle Jenne noted "it's taking some time for HCPs to adopt this new approach" because it is the "only approved treatment." Just last quarter Jeanne claimed "TRYNGOLZA is on track to meet our full year 2026 revenue guidance and positioned to achieve our projections for more than $3 billion in peak annual revenue." The investigation concerns whether Ionis Pharmaceuticals, Inc. adequately disclosed the slower commercial launch momentum and sales trajectory of TRYNGOLZA ahead of the guidance reduction on November 9, 2026.

Get Started